Frank Boeckler

Frank M. Boeckler his Ph.D. in Medicinal Chemistry at the University of Erlangen (Germany) in 2004 under supervision of Prof. Peter Gmeiner. He specialized in computational chemistry and drug design, ranging from QM methods to in silico screening. In 2006, he joined Prof. Sir Alan R. Fersht at the MRC Center for Protein Engineering in Cambridge/UK as Marie Curie fellow and discovered there p53 mutant stabilizers as potential new cancer therapeutics. While working in Cambridge at the interface of experiment and theory, he focused on molecular biology and biophysics. In 2008, he was appointed as Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich.

In 2010, he moved to Eberhard Karls University Tuebingen as Professor for Medicinal Chemistry/Drug Design, where he now heads the Laboratory for Molecular Design & Pharmaceutical Biophysics. His work is dedicated to understanding molecular interactions as the foundation for chemical biology and drug research and to apply theoretical and biophysical methods to cancer research, particularly, for targeting the kinome and the p53 network. He has receive several awards including the Klaus-Grohe Award for Medicinal Chemistry (2005), the PHOENIX Pharmazie-Wissenschaftspreis (2008), and the EFMC Prize for a Young Medicinal Chemist in Academia (2016). In addition, he serves as co-editor of the ROEMPP (Thieme) and editor-in-chief of Drug Design, Development and Therapy.

Topic: http://www.echeminfo.com/workshop/application-halogen-bonding-drug-discovery